{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/NAGE/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-29T05:36:23.143Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":6364,"canonical_name":"Niagen Bioscience, Inc.","cik":"0001386570","uei":null,"lei":null,"duns":null,"ticker":"NAGE"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":16},"count":16,"timeline":[{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Niagen Bioscience, Inc. — 2026-07-08","url_slug":"/sec/cik-0001386570/4/0001834681-26-000001","accession_number":"0001834681-26-000001","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Niagen Bioscience, Inc. — 2026-07-08","url_slug":"/sec/cik-0001386570/4/0002042509-26-000001","accession_number":"0002042509-26-000001","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Niagen Bioscience, Inc. — 2026-07-08","url_slug":"/sec/cik-0001386570/4/0001417952-26-000002","accession_number":"0001417952-26-000002","importance":30},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Pamir Ozan","title":"Chief Financial Officer","shares":4255,"price_per_share":2.71,"usd_value":11531,"security_title":"Common Stock","importance":15.01153105},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Lopez Carlos Luis","title":"SVP, General Counsel","shares":2314,"price_per_share":2.71,"usd_value":6271,"security_title":"Common Stock","importance":15.00627094},{"ts":"2026-06-30","kind":"sec.insider.a","reporter":"Fried Robert N","title":"Chief Executive Officer","shares":1106,"price_per_share":2.71,"usd_value":2997,"security_title":"Common Stock","importance":15.00299726},{"ts":"2026-06-29","kind":"sec.filing","form_type":"8-K","title":"8-K — Niagen Bioscience, Inc. — 2026-06-29","url_slug":"/sec/cik-0001386570/8-k/0001386570-26-000035","accession_number":"0001386570-26-000035","importance":35},{"ts":"2026-06-29","kind":"sec.filing","form_type":"S-3","title":"S-3 — Niagen Bioscience, Inc. — 2026-06-29","url_slug":"/sec/cik-0001386570/s-3/0001213900-26-072796","accession_number":"0001213900-26-072796","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"4","title":"4 — Niagen Bioscience, Inc. — 2026-06-26","url_slug":"/sec/cik-0001386570/4/0001437237-26-000001","accession_number":"0001437237-26-000001","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"4","title":"4 — Niagen Bioscience, Inc. — 2026-06-26","url_slug":"/sec/cik-0001386570/4/0001713918-26-000001","accession_number":"0001713918-26-000001","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"4","title":"4 — Niagen Bioscience, Inc. — 2026-06-26","url_slug":"/sec/cik-0001386570/4/0001769529-26-000003","accession_number":"0001769529-26-000003","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"4","title":"4 — Niagen Bioscience, Inc. — 2026-06-26","url_slug":"/sec/cik-0001386570/4/0001896252-26-000001","accession_number":"0001896252-26-000001","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"4","title":"4 — Niagen Bioscience, Inc. — 2026-06-26","url_slug":"/sec/cik-0001386570/4/0001923843-26-000001","accession_number":"0001923843-26-000001","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"4","title":"4 — Niagen Bioscience, Inc. — 2026-06-26","url_slug":"/sec/cik-0001386570/4/0001942711-26-000001","accession_number":"0001942711-26-000001","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"4","title":"4 — Niagen Bioscience, Inc. — 2026-04-27","url_slug":"/sec/cik-0001386570/4/0001417952-26-000001","accession_number":"0001417952-26-000001","importance":30},{"ts":"2026-04-24","kind":"sec.insider.m","reporter":"Fried Robert N","title":"Chief Executive Officer","shares":20000,"price_per_share":2.61,"usd_value":52200,"security_title":"Common Stock","importance":15.0522}]}